Full Fed. Circ. Skips Biogen Fight Over MS Drug Patent
Biogen lost another bid on Wednesday to ward off competition for its blockbuster multiple sclerosis drug Tecfidera, as the full Federal Circuit said it wouldn't reconsider a panel decision that Banner...To view the full article, register now.
Already a subscriber? Click here to view full article